Compare Goldman Sachs Physical Gold ETF (AAAU) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Physical Gold ETF vs Alnylam Pharmaceuticals, Inc. — how do they compare? Goldman Sachs Physical Gold ETF trades at $43.36, while Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B). The key difference: Goldman Sachs Physical Gold ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| AAAU | ALNY | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $53.21 | $491.22 |
52-Week Low | $32.74 | $205.48 |
Market Cap | — | $29.60B |
Enterprise Value | — | $27.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAAU, a US-listed gold-focused asset, trades at $43.52, up 0.58% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights gold's strength amid cooling US inflation and geopolitical tensions, with spot gold hitting $4,438/oz. The stock lacks disclosed financial ratios, indicating potential data gaps for fundamental analysis.
The outlook for AAAU is tied to gold's momentum, supported by Fed policy expectations and safe-haven demand, but risks include volatility from economic data and overbought conditions. Investors should weigh gold's bullish trends against the absence of company-specific fundamentals and high RSI levels suggesting near-term caution.
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Goldman Sachs Physical Gold ETF
AAAU tracks the price of gold bullion by holding physical gold bars in secure vaults. Managed by Goldman Sachs, this ETF offers a cost-effective way to gain direct exposure to gold without the logistical challenges of storage or insurance.
Read more on AAAU →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
